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Abstract
Background Erythropoiesis-stimulating agents (ESAs)
are used for the management of anaemia in patients with
non-myeloid malignancies where anaemia is due to the
effect of concomitant myelosuppressive chemotherapy.
Assessing the impact of different ESA dosing regimens on
office staff time and projected labour costs is an important
component of understanding the potential for optimization
of oncology practice efficiencies.
Objectives A two-phase study was conducted to evaluate
staff time and labour costs directly associated with ESA
administration in real-world oncology practice settings
among cancer patients undergoing chemotherapy. The
objective of Phase 1 was to determine the mean staff time
required for the process of ESA administration in patients
with anaemia due to concomitantly administered chemo-
therapy. The objective of Phase 2 was to quantify and
compare the mean staff time and mean labour costs of ESA
administered once weekly (qw) with ESA once every
3 weeks (q3w) over an entire course of chemotherapy.
Methods Phase 1 was a prospective, cross-sectional time
and motion study conducted in six private oncology prac-
tices in the US based on nine steps associated with ESA
administration. Using findings from Phase 1, Phase 2 was
conducted as a retrospective chart review to collect data on
the number and types of visits in two private oncology
practices for patients receiving a complete course of
myelosuppressive chemotherapy.
Results In Phase 1, the mean total time that clinic staff
spent on ESA administration was 23.2 min for patient
visits that included chemotherapy administration
(nchemo = 37) and 21.5 min when only ESA was admin-
istered (nESAonly = 36). In Phase 2, the mean duration of
treatment was significantly longer for q3w than qw
(53.84 days for qw vs. 113.38 for q3w, p \ 0.0001); thus,
analyses were adjusted using analysis of covariance
(ANCOVA) for episode duration for between-group com-
parisons. Following adjustment by ANCOVA, qw darbe-
poetin alfa (DA) patients (nqw = 83) required more staff
time for ESA ? chemotherapy visits and ESA-only visits
than q3w patients (nq3w = 118) over a course of chemo-
therapy. Overall, mean total staff time expended per che-
motherapy course was greater for patients receiving qw
versus q3w DA. Weekly DA dosing was associated with
greater projected mean labour costs ($US38.16 vs.
$US31.20 [average for 2007–2010]).
Conclusions The results from this real-world study
demonstrate that oncology practices can attain staff time
and labour costs savings through the use of q3w ESA. The
degree of savings depends on the individual oncology
practice’s staffing model and ESA administration pro-
cesses, including those that allow for optimized synchro-
nization of patient visits for ESA and chemotherapy
administration. These findings indicate that additional
research using standard ESA administration protocols for
longer periods of time with a larger number of oncology
practices and patients should be conducted to confirm these
findings.
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1 Background
While chemotherapeutic approaches to the treatment of
cancer are evolving, anaemia, characterized by reduced
levels of red blood cells, lower-than-normal levels of hae-
moglobin in red blood cells, or both, continues to be a
common adverse effect of these regimens. Anaemia affects
an estimated 1.3 million cancer patients in the US [1]. Ery-
thropoiesis-stimulating agents (ESAs) increase haemoglobin
levels and reduce the need for red blood cell transfusions [2].
However, to gain these ESA treatment benefits may require
additional patient clinic visits, which may consume addi-
tional staff time and clinic resources, in addition to imposing
time burdens on the patients and their caregivers [3].
Long-acting ESAs have the potential to improve practice
efficiency by allowing longer time intervals between doses,
reducing the overall number of doses needed over the course
of the chemotherapy regimen and staff time requirements
[4, 5]. Darbepoetin alfa (DA) is a long-acting ESA that may be
administered either every week (qw) or every 3 weeks (q3w)
[6]. Studies suggest that the use of long-acting agents lessens
patient and staff time requirements [4, 7–14]. Questions
remain on how dosing flexibility of ESAs in clinical practice
impacts on oncology practice staff time, especially regarding
completion of activities associated with the administration of
ESAs. While there have been previous studies quantifying
ESA administration time, not all events and times were
included in those studies [3–5, 15]. To better define and
evaluate the efficiencies of ESA dosing in the oncology
practice setting, a study comprised of two separate phases was
conducted. The first phase was a prospective, cross-sectional
time and motion study designed to determine the mean time
required to complete the process of ESA administration in the
US. The primary outcome measure was the observed and
recorded time required to complete each of the nine tasks
involved in ESA administration, with and without concomi-
tant chemotherapy administration. Phase 2 was conducted as a
retrospective chart review pilot designed to collect the fre-
quency of visits where ESA administration, haemoglobin
determinations and chemotherapy administration occurred
together or separately. Results from the two phases were then
combined to compare time and labour cost in actual clinical
care in two private oncology practices for patients receiving a
complete course of myelosuppressive chemotherapy.
2 Methods
2.1 Phase 1 Prospective, Cross-Sectional,
Observational Time and Motion Study
Phase 1 included a prospective time and motion study
designed to determine the mean time required to complete
each of nine identified distinct steps in the process of ESA
administration. This phase was conducted in six private
oncology practices throughout the US (two sites in the mid-
Atlantic, and one site each in the southeast-Atlantic, south,
mid-west and west). Study data were collected between
February and April of 2010. To be eligible for inclusion in
the study, sites had to provide at least 12 patients for
observation of time and motion procedures. In addition, the
practice was required to demonstrate sufficient patient
volume (i.e. at least 15 unique patient visits for anaemia
due to concomitantly administered chemotherapy-related
ESA administration between 1 August 2009 and 1
November 2009, including more than six ESA-only visits
and more than six visits for concomitant ESA and che-
motherapy administration).
Adult patients receiving myelosuppressive chemother-
apy for the treatment of solid tumour malignancies,
including but not limited to breast, lung, gastrointestinal,
uterine, cervical, ovarian and lymphoma, were eligible for
inclusion. Patients under the age of 18 years or with a
history of myelodysplastic syndrome or renal disease were
excluded from analysis. In addition, duplicate patient visits
and visits in which patients did not undergo all of the nine
required components of ESA administration were excluded
from the study. The study was Institutional Review Board
(IRB)-approved and each patient participant provided
written informed consent.
A total of 12 patient visits were selected per site; of
these, six assessments evaluated ESA-only visits, while the
remaining six evaluations included visits in which patients
received an ESA in combination with chemotherapy.
Independent study data monitors collected and recorded all
data, and a stopwatch was used to record start and stop
points for each of the nine events related to ESA admin-
istration. Patient visits with and without concomitant che-
motherapy were analysed separately.
2.1.1 Data Points
The outcome data were the time required to complete each
of the following nine standard tasks involved in ESA
administration, with and without concomitant chemother-





5. patient counselling/preparation/vital signs
6. ESA preparation
7. ESA administration and documentation
8. patient billing
9. patient appointment scheduling
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At each site, a trained observer recorded the time for
each step, in minutes and seconds, using a stopwatch. The
start and stop times were recorded on the case report form.
The time needed to fulfil ESA Risk Evaluation and
Mitigation Strategies requirements was not included in the
observation, as this is a prescriber activity, as opposed to
one that is performed by clinic staff.
2.1.2 Statistical Analysis
Mean times to complete individual tasks and all tasks and
corresponding 95 % confidence intervals were estimated
using linear mixed-effect models with site as a random
effect to account for the clustering effect within each site.
2.2 Phase 2 Retrospective Chart Review
Phase 2 was conducted as a retrospective chart review
collecting information about ESA administration, haemo-
globin determinations and chemotherapy administration for
adult patients initiating chemotherapy between 1 August
2007 and 31 December 2010. Patients were included if they
were treated for solid tumour malignancies, including lung,
colorectal, prostate, ovary, lymphoma, metastatic breast
and metastatic head/neck. All subjects had to have received
DA therapy on a qw or q3w regimen, and have all treat-
ment records (i.e. chemotherapy, DA administration, hae-
moglobin values) available for review. Patients under the
age of 18 years, with other types of tumours, who received
any portion of their chemotherapy regimen outside of the
specified time frame, who received an ESA other than DA
or who initiated DA on an alternative schedule were
excluded from this analysis.
Eligible records were identified via electronic query of
the electronic medical record/billing databases of the two
private oncology practices that employ qw or q3w DA
administration as a standard practice. Following electronic
identification, a manual chart review was conducted to
eliminate records based on inclusion/exclusion criteria, and
to gather study data from acceptable records. Records were
searched until all available records were exhausted. This
phase was IRB-approved and Health Insurance Portability
and Accountability Act (HIPPA) compliant.
2.2.1 Data Points
Data points for the retrospective chart review were the
mean number of clinic visits over a complete course of
chemotherapy, classified as:
• ESA-only visits
• ESA ? chemotherapy visits
• haemoglobin check-only visits
2.2.2 Combining Results of Phases 1 and 2
Results of the two phases were then combined to compare
time and labour cost in actual clinical care in two private
oncology practices for patients receiving a complete course
of myelosuppressive chemotherapy. By multiplying the
time for a visit by the number of visits, the total time could
be determined over an entire course of chemotherapy.
Staff resource costs were based on the U.S. Bureau of
Labor Statistics national average for the study years
(2007–2010) relative to hourly wage rates for various
personnel involved in the ESA administration process (e.g.
nurses, receptionists, medical technologists, phlebotomists,
laboratory technicians); wage rates were multiplied by the
actual mean time expended by clinic staff for each com-
ponent of DA administration. The resultant mean were then
multiplied by the mean number of clinic visits, in order to
determine the mean total labour cost for each visit type.
Total labour cost data was then obtained and compared for
each DA administration regimen.
Secondary study outcomes included:
• total number of DA-related patient visits; and
• percentage of planned DA doses not administered (i.e.
missed planned doses).
An ESA dose was considered ‘‘administered as plan-
ned’’ if it was given as scheduled, within a window of
±2 days. Patients on a qw regimen were expected to
receive the ESA between 5 and 9 days following their
previous dose, while those on a q3w regimen were
expected to receive the ESA between 19 and 23 days after
their previous dose; planned ESA doses that were not
administered before or within this timeframe, due to hae-
moglobin higher than 10 g/dL, were considered ‘‘missed
planned doses.’’ Analyses were conducted to identify the
impact of DA administration frequency on these secondary
outcome measures.
2.2.3 Statistical Analysis
A sample size of 78 patients per group was deemed suffi-
cient to test for differences between groups, with an
anticipated moderate effect size of 0.4 at an alpha level of
0.05, with a desired statistical power of 0.8. Summary
statistics (i.e. mean, median, standard deviation) were
calculated for all outcome measures. The one-tailed t-test
was used to compare the means of key variables (i.e. staff
time expended, staff resource cost, number of DA-related
patient visits, percentage of planned DA doses not
administered), and the chi-square test was applied to
compare proportions. Furthermore, cost data were log-
transformed and analysed with the one-tailed t-test.
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Analysis of covariance (ANCOVA) was used to adjust for
the difference in treatment duration for the two groups.
3 Results
3.1 Phase 1 Prospective, Cross-Sectional,
Observational Time and Motion Study
Seventy-three patient visits were included in the staff time
and motion study (patient visits when only ESA was
administered [nESA only] = 36, patient visits that included
chemotherapy administration [nchemo] = 37). As shown in
Table 1, the mean total time that oncology practice staff
spent to complete all of the nine tasks of ESA adminis-
tration was 23.2 min for patient visits that included che-
motherapy administration. The most time-consuming
individual steps were laboratory and phlebotomy, with
mean times of 7.0 (95 % CI 3.1–10.9) and 3.7 (95 % CI
2.0–5.5) min, respectively. For patient visits that did not
include chemotherapy administration, the mean total time
spent to complete all nine tasks was 21.5 min. The most
time-consuming individual steps were laboratory and
phlebotomy, requiring 6.7 (95 % CI 4.4–9.1) and 3.6
(95 % CI 2.3–4.8) min, respectively. A haemoglobin
check-only visit was estimated at a mean time of 16.5 min.
3.2 Phase 2 Retrospective Chart Review
A total of 195 patients were included in the phase pilot (qw
DA patients [nqw] = 83; q3w DA patients [nq3w] = 112).
The majority of study subjects were female and there were
no significant differences in age or ethnicity between the
groups (Table 2). Predominant cancer types included lung,
ovarian, colorectal, lymphoma and metastatic breast.
Ovarian cancer patients were more likely to receive q3w
than qw DA, while colorectal and metastatic head/neck
patients more often received qw than q3w DA. The mean
duration of treatment was significantly longer for q3w than
qw (53.84 days for qw vs. 113.38 days for q3w,
p \ 0.0001); thus, analyses were adjusted using ANCOVA
for episode duration for between-group comparisons.
3.3 Results Adjusted by ANCOVA
Patients receiving qw DA required more staff time for
ESA ? chemotherapy visits than those receiving q3w
(67.51 vs. 60.09 min [Table 3]). Overall, the mean total
staff resource time expended per chemotherapy course was
greater for patients receiving weekly versus q3w DA
(120.69 vs. 112.45 min). Weekly DA dosing was associ-
ated with greater mean labour costs for ESA ? chemo-
therapy visits and ESA-only visits than q3w dosing
($US21.18 vs. $US18.82 and $US12.75 vs. $US3.85;
average for 2007–2010 [Table 4]). Q3w dosing resulted in
greater mean labour costs for haemoglobin check-only
visits than qw DA administration ($US13.53 vs. $US4.93).
Overall, patients receiving qw versus q3w DA therapy
imposed higher mean total labour costs per patient related
to DA administration and haemoglobin monitoring
throughout the entire course of chemotherapy ($US38.16
vs. $US31.20).
The mean number of total patient visits related to DA
administration was 4.90 visits for the qw group compared
with 6.08 for the q3w group. Following adjustment for
inter-group variance, there was no difference in total
patient visits between groups (5.56 for qw therapy vs. 5.59
for q3w therapy).
Table 1 Mean observed times to complete the nine-step erythropoiesis-stimulating agent administration process with or without chemotherapy
included in the patient visit





Patient registration/check-in 3.0 (0.0–8.3) 2.2 (1.1–3.4) 2.2
Phlebotomy 3.7 (2.0–5.5) 3.6 (2.3–4.8) 3.6
Laboratory 7.0 (3.0–10.9) 6.7 (4.4–9.1) 6.7
Chart retrieval 0.3 (0.1–0.5) 0.3 (0.2–0.4) 0.3
Patient counselling, preparation and evaluation of vital signs 2.3 (1.7–2.9) 2.3 (1.9–2.7)
ESA preparation 1.1 (–3.2 to –5.5) 1.4 (0.8–1.9)
ESA administration and documentation 1.4 (0.3–2.5) 1.3 (0.9–1.8)
Patient billing 1.7 (0.4–3.0) 1.7 (0.5–2.9) 1.7
Patient appointment scheduling 2.7 (0.7–4.8) 2.0 (0.3–3.6) 2.0
Total time to complete all tasks 23.2 (16.8–29.6) 21.5 (14.4–28.8) 16.5
Data are given as the mean number of minutes observed to complete the task (95 % CI)
ESA erythropoiesis-stimulating agent
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4 Discussion
The current study provides unique insights into clinical
oncology practices utilizing different ESA dosing regi-
mens. The time and motion assessment, using the nine-step
standardized process of ESA administration, found a total
mean time of 23.2 min for patient visits that included
chemotherapy administration and 21.5 min for visits that
involved ESA administration alone. This evaluation dem-
onstrated that the measured time for the process of ESA
administration was similar regardless of whether chemo-
therapy administration was included in the visit or not.
In the second phase, there was significantly longer
duration of ESA treatment for the q3w regimen than for the
qw regimen. Following ANCOVA adjustment for inter-
group variance, patients receiving qw versus q3w DA
therapy imposed higher mean total labour costs per patient
related to DA administration and haemoglobin monitoring
throughout the entire course of chemotherapy ($US38.16
vs. $US31.20).
Cross-sectional studies such as this one give practices
the ability to examine their office systems for areas that
may be streamlined, and to identify potential differences
between ESA regimens in terms of time requirements. The
opportunity cost of such time differences may be signifi-
cant and should be taken into account when selecting
anaemia management options. Specifically, clinics may
optimize the practice efficiency of ESA therapy by offering
anaemia management strategies that require less frequent
administration, thereby reducing the time burden for staff
[5, 16]. Clinics utilizing q3w ESA administration may
synchronize ESA therapy with current chemotherapy reg-
imens, thereby eliminating the need for ESA-only visits.
This may offer an opportunity for efficiency, as study
findings indicate that the additional time to administer an
ESA during a chemotherapy visit is negligible. Freeing up
time may allow clinics flexibility in staff scheduling, per-
formance of other clinical activities, scheduling of new
patients, and could shorten the time of referral to the
oncology clinic.
The prospective time and motion phase has several
potential limitations. First, the site selection criteria were
based on sites with significant ESA patient volume. The
non-random selection of sites limits the generalizability of
these findings beyond similar practices within similar
geographic locations. However, this study included a
more complete assessment of the total events associated
with ESA administration than have been previously
examined.
Second, this study assumes that the time spent on ESA-
related tasks during the visits was the same regardless of
dose regimen (q3w vs. qw). In real-world practice, there
might be a difference in time burden to the office staff in
administering one regimen versus the other; however,
since the process of ESA administration within a visit was
standardized, any difference is unlikely to be substantive.
Measurement error could have occurred due to variation
in trained observer start and stop points. To minimize
measurement error, data collectors were trained before the
study was initiated and the tasks had clearly defined
starting and stopping events to reduce the possibility for
differences in interpreting the start and stop of a task.
Lastly, if a patient had prior experience and knowledge
with receiving ESAs, this could impact the amount of time
a site staff member needed to spend counselling the patient
and monitoring the patient after ESA administration. The
quantity of paperwork and preliminary diagnostics could
also have varied between new patients to the clinic and
returning patients.









Number of patients 83 112a
Age, years (SD) 59.5 (9.8) 62.3 (13.3) NS
Gender
Male 20 (24.1) 18 (16.1) NS
Female 63 (75.9) 94 (83.9) NS
Ethnicity
Unknown 1 (1.2) 5 (4.5) NS
Hispanic or Latino 3 (3.6) 0 NS
Not Hispanic or
Latino
79 (95.2) 107 (95.5) NS
Cancer type
Lung 27 (32.5) 23 (20.5) NS
Ovarian 12 (14.5) 36 (32.1) 0.0056
Colorectal 13 (15.7) 6 (5.4) 0.0216
Prostate 2 (2.4) 3 (2.7) NS
Lymphoma 6 (7.2) 11 (9.8) NS
Metastatic breast 15 (18.1) 25 (22.3) NS
Metastatic head/neck 7 (8.4) 2 (1.8) 0.0466
Lung, metastatic
breast
0 1 (0.9) NS
Lung, metastatic
head/neck
1 (1.2) 1 (0.9) NS




53.84 (55.46) 113.38 (83.81) \0.0001
Values are presented as n (%) unless specified otherwise
ESA erythropoiesis-stimulating agent, NS non-significant, q3w once
every 3 weeks, qw once weekly
a Site 1 subject 50 was excluded due to excessive visitation frequency
(257 visits)
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In the retrospective chart evaluation phase, examination
of staff resources and costs associated with administration
of supportive care, such as ESA therapy, in relation to
chemotherapy represents an important approach to
improving the overall quality and efficiency of an outpa-
tient oncology practice. As shown by the results of our
current study, patients receiving qw DA required more staff
time for ESA ? chemotherapy visits and ESA-only visits
than those receiving q3w DA, while patients receiving q3w
DA required more staff time for haemoglobin check-only
visits than those receiving weekly therapy. Overall, mean
total staff resource time expended per chemotherapy course
was greater for patients receiving qw versus q3w DA. In
addition, qw DA dosing was associated with greater mean
labour costs for ESA ? chemotherapy visits and ESA-only
visits than q3w DA. When the patient groups were adjusted
using ANCOVA, q3w DA dosing resulted in greater mean
labour costs for haemoglobin check-only visits than qw DA
administration.
The study presented here is the collection of data from
actual clinical practice, utilizing two different methodolo-
gies, which served to both validate previously conducted
studies as well as enable a real-world, real-time time and
motion and economic assessment. The findings reported
here provide very detailed data into the actual the cost
impact of qw vs. q3w ESA administration using different
assessment methodologies and together provided valuable
insights into maximizing the cost benefits of ESA use in
real-world patient care settings.
5 Conclusion
The findings from this study demonstrate that implemen-
tation of a q3w dosing schedule with a long-acting ESA for
treatment of anaemia due to concomitantly administered
chemotherapy which more closely coincides with many
patients’ chemotherapy schedules, can minimize ESA-only
visits, reducing staff time, staff resources and total labour
costs. The methodology used in this study can be imple-
mented in the real-world oncology setting and represents a
potential opportunity for increased operational efficiency
for oncology practices.
In summary, the introduction of ESAs into clinical
oncology practice has been an advance in the management
of patients with anaemia undergoing chemotherapy. The
results from the study presented here detail how the
implementation of a q3w dosing schedule with a long-
acting ESA, which often more closely coincides with
patients’ chemotherapy schedules, may minimize ESA-
only visits, reducing staff time and total labour costs in
settings that represent real-world practice.
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ESA-only visits 1.89 21.5 40.64 0.57 21.5 12.26
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Table 4 Mean staff cost by visit type (adjusted by ANCOVA)













ESA-only visits 1.89 6.75 12.75 0.57 6.75 3.85
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